Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jeffrey G. Lamothe
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Beta
- 1.61
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -33.10
Financials
Revenue
$0.00-100.0%Net Income
$-6.36MEBITDA
$-6.53MFree Cash Flow
$-5.45MEPS (diluted)
$-5.31Shares Outstanding (diluted)
1.20M+21768081.2%Operating Expenses
$6.44MCash & Debt
$9.80MReturn of Capital
$1.0KRevenue by Segment (annual)
$32.40MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-25.97M | $-87.27 |
| 2024 | $0.00 | $-24.13M | $-31458.00 |
| 2023 | $0.00 | $-17.41M | $-834044.00 |
| 2022 | $3.11M | $8.03M | $922390.00 |
| 2021 | $12.29M | $-28.46M | $-3557646.00 |
| 2020 | $4.31M | $-17.75M | $-5546028.00 |
| 2019 | $0.00 | $-44.70M | $-125727793.00 |
| 2018 | $23.07M | $-53.69M | $-19578811.00 |
| 2017 | $14.66M | $6.97M | $-17584638.00 |
| 2016 | $36.43M | $-112.42M | $-45538416.00 |
| 2015 | $33.60M | $-59.32M | $-24041001.00 |
| 2014 | $45.63M | $-51.12M | $-20712512.00 |
| 2013 | $170.0K | $-53.34M | $0.00 |
Valuation
APVOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (5)
- Newsaccessnewswire.com·12d ago·Neutral
…tivating Immune Cells and Addressing Tumor Defenses SEATTLE, WA / ACCESS Newswire / September 24, 2026 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced progress in its next-generation trispecific programs. The Company is optimizing several trispecific candidates for reliable, scalable man…
View source ↗ - Newsbenzinga.com·32d ago·Neutral
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial Aptevo Therapeutics Inc. (NASDAQ:APVO) announced that its lead candidate mipletamig achieved a 93% clinical benefit rate when administered as a triplet therapy to frontline acute myeloid leukemia patients carrying TP53 mutations.
View source ↗ - Newsaccessnewswire.com·53d ago·Positive
…tline AML Data, Path Toward Phase 2 Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline Non-Dilutive Grant Funding Advances APVO451 and Validates Trispecific Solid Tumor Strategy Strategic Niowave Collaboration Opens a New Radiopharmaceutical Therapeutic Development Opportunity SEATTLE, WA / ACCESS Newswire / August 14, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics base…
View source ↗ - Newsaccessnewswire.com·53d ago·Negative
…ces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds SEATTLE, WA / ACCESS Newswire / August 13, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today closed its previously announced warrant inducement transaction with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have exercised in f…
View source ↗ - Newsaccessnewswire.com·55d ago·Negative
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds SEATTLE, WA / ACCESS Newswire / August 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced it has entered into warrant inducement letter agreements with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holde
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-3.72 per share
Typical surprise -14.5% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-5.31 vs $-6.01beat
- Wed, May 13$-6.41 vs $-5.60miss
- Fri, Mar 20$1684.47 vs $-8.09beat
- Thu, Nov 6$-40.11 vs $-37.59miss
- Mon, Aug 11$-151.20 vs $-83.20miss
- Thu, May 15$-1579.14 vs $-4.21miss
Estimates and results for APVO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by APVO officers and directors.
- Bought
- $20k
- Sold
- —
1 trade
0 trades
- Grant Grady Iiibought
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Stephen Cohenhouse · TN09 · disclosed Jul 3, 2019 (9d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.